Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.
Liu G, LoRusso P, Heath E, Bruce J, Traynor A, Pilat M, Breazna A, Tortorici M, Shalinsky D, Ricart A. Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study. Journal Of Clinical Oncology 2010, 28: 3033-3033. DOI: 10.1200/jco.2010.28.15_suppl.3033.Peer-Reviewed Original Research